<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164005</url>
  </required_header>
  <id_info>
    <org_study_id>2016CFA025</org_study_id>
    <nct_id>NCT03164005</nct_id>
  </id_info>
  <brief_title>The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease</brief_title>
  <acronym>Obesity</acronym>
  <official_title>The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will enroll about 120 subjects from the hospital's healthcare center. The
      investigators will collect the basic informations, blood pressure, body mass index, fasting
      blood glucose and fasting blood lipids of each subject. The investigators will collect the
      blood samples and then test them for fasting insulin levels, VEGF-B levels, the gene promoter
      region methylation status and the genomic protein methylation levels of the VEGF-B gene of
      the cells，and finally do the statistical analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll about 120 subjects from the hospital's healthcare center, and
      these 120 subjects will be divided into four groups: normal weight with or without metabolic
      diseases and obesity with or without metabolic diseases. Each group has 30 subjects. The
      investigators will collect the basic information(name, gender，age, medical history，family
      history, etc.), blood pressure, body mass index, fasting blood glucose and fasting blood
      lipids of each subject from the healthcare center. The investigators will collect the blood
      samples of each subject,separate the plasma and then test the fasting insulin, VEGF-B levels
      by ELISA. The investigators will separate the peripheral blood mononuclear cells from the
      blood, and then test the gene promoter region methylation status of the VEGF -B gene by PCR
      and the bisulfite-modified sequencing and test the genomic protein methylation level of the
      VEGF-B gene by chromatin immunoprecipitation assay(CHIP) and real-time quantitative PCR of
      the cells，and finally do the statistical analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting insulin and blood VEGF-B levels</measure>
    <time_frame>3 days</time_frame>
    <description>To investigate the relationship between blood pressure, BMI, fasting blood glucose, fasting blood lipids and fasting insulin and blood VEGF-B levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level .</measure>
    <time_frame>7 days</time_frame>
    <description>To investigate the relationship between the methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level and obesity and metabolic disorders.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Normal weight subjects without metabolic diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Normal weight subjects with metabolic diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Obesity subjects without metabolic diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Obesity subjects with metabolic diseases</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma，Peripheral blood mononuclear cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obesity (BMI ≥ 28kg/m2) subjects without metabolic diseases ,or obese subjects with
        metabolic diseases, Or normal body weight (18.5 kg/m2 ≤ BMI &lt;24 kg/m2) subjects without
        metabolic diseases, or normal body weight subjects with metabolic diseases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with normal weight(18.5kg/m²≤BMI＜24kg/m²）or obesity(28kg/m²≤BMI）

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Lulu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Xiaofeng</last_name>
    <phone>+86 18086482871</phone>
    <email>yexf2016@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kong Wen</last_name>
    <phone>+86 027-85726798</phone>
    <email>wenly-kong@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Xiaofeng</last_name>
      <phone>+86 18086482871</phone>
      <email>yexf2016@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Kong Wen</last_name>
      <phone>+86 027-85726798</phone>
      <email>wenly-kong@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Ishraq Zafar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Lulu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 21, 2017</last_update_submitted>
  <last_update_submitted_qc>May 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Chen Lulu</investigator_full_name>
    <investigator_title>Head of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>VEGF-B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

